5 completed, 5 recruiting. 7 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 2 |
| Phase 2 | 3 | Recruiting 3 |
| Phase 3 | 2 | Recruiting 2 |
Follow Opevesostat: new trials by email Literature Review of Opevesostat trials Research Report on Opevesostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) Opevesostat, Prednisone, Fludrocortisone acetate - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2026-05-11 | 2026-06-25 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) Opevesostat, Prednisone, Fludrocortisone acetate - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2025-05-13 | 2026-02-24 |
| A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) Opevesostat, Prednisone, Fludrocortisone acetate - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-12-18 | 2025-05-25 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-21 |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-01-30 | 2026-03-19 |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Opevesostat, Abiraterone acetate, Enzalutamide - Prostate Cancer Metastatic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1310 | 2023-12-31 | 2026-10-06 |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Opevesostat, Dexamethasone, Fludrocortisone acetate - Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1314 | 2023-12-18 | 2026-10-20 |
| A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 7 | 2023-11-14 | 2026-04-27 |
Prostatic Neoplasms (3) · Prostatic Neoplasms, Castration-Resistant (2) · Neoplasm Metastasis (1) · Neoplasms (1)
United States (8) · Canada (5) · Chile (5) · Spain (5) · Taiwan (5) · Turkey (Türkiye) (5) · United Kingdom (5) · Australia (4) · Brazil (4) · France (4) · Germany (4) · Ireland (4) · Israel (4) · Italy (4) · Japan (4)
2023 (3)